To the editor: We read the interesting secondary analysis of the 4.9-year Treating to New Targets (TNT) study1 reporting the effects of aggressive low-density lipoprotein cholesterol lowering in women (median age 63.5 years) with stable coronary heart disease. In view of the reported data, we have serious concerns about the large excess in cancer mortality seen among the women randomised to high-dose atorvastatin (80 mg daily) therapy compared with …